Morning Seminar Vol 3(1) July 2005

Prognostic factors for relapsed childhood ALL: impact of allogeneic SCT – a report from the Kyushu-Yamaguchi Children’s Cancer Study Group (Matsuzaki, Pediatr Blood Cancer 2005) 1

JACLS Seminar (2005) 5

Kaposiform hemangioendotherioma without Kasabach-Merritt phenomenon (Gruman, J Am Acad Dermatol 2005) 20

2nd JPLSG (2005.6) 24

Management of recurrent NB 27

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001 (Steinbach, Clin Invest Disease 2003) 39

8th International childhood ALL workshop Ponte di Legno 42

Enteral metronidazole for the prevention of GVHD in pediatric marrow transplant recipients: results of a pilot study (Guthery, BMT 2004) 47

B. cereus infection 48

Voriconazole compared with liposomal Amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever (Walsh, N Engl J Med 2002)
Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis (Herbrecht, N Engl J Med 2002) 50

4th Japanese Pediatric Brain Tumor Consortium (2005.6.25) 54

SVC syndrome of malignant origin (Porte, Eur J Cardiothorac Surg 2000) 59

45th Pediatric Cancer Conference (2005.6.11) 64

Methotrexate in SLE (Wong, Lupus 2005) 67

Reduced intensity haemopoietic SCT for treatment of non-malignant disease in children (Jacobsohn, Lancet 2004) 70

Aspergillus niger infection in patients with haematological disease: a report of eight cases (Fianchi, Mycoses 2004) 74

An infant with systemic hypertension, renal artery stenosis, and NB (Shinohara, J Pediatr Surg 2004) 76

Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive ALL (Ph ALL) (Wassmann, Blood 2005) 80

Paclitaxel for ovarian cancer　83